How should I calculate a patient’s 10‑year atherosclerotic cardiovascular disease (ASCVD) risk and determine appropriate statin therapy?

ASCVD Risk Calculation and Statin Therapy Determination

Use the Pooled Cohort Equations (PCE) to calculate 10-year ASCVD risk for patients aged 40-75 years, then apply the 2018 ACC/AHA guideline thresholds to determine statin intensity based on risk category, diabetes status, and LDL-C levels. 1

Risk Calculation Approach

Calculate 10-year ASCVD risk using the Pooled Cohort Equations for adults aged 40-75 years without established ASCVD. While the newer PREVENT equations (2023) exist, recent evidence shows they underestimate risk in patients not on statins by approximately 50% compared to observed outcomes 2. The PCE more accurately reflects untreated risk, which is what you need for initial treatment decisions 2.

Key Variables for PCE Calculation:

• Age, sex, race (Black vs non-Black)
• Total cholesterol and HDL-C
• Systolic blood pressure and treatment status
• Diabetes mellitus status
• Current smoking status

Statin Therapy Algorithm

Immediate High-Intensity Statin (No Risk Calculation Needed)

Start high-intensity statin therapy without calculating 10-year risk in these populations 1:

• LDL-C ≥190 mg/dL: Begin high-intensity statin immediately
• Clinical ASCVD: Use maximally tolerated statin to reduce LDL-C by ≥50%

Diabetes Mellitus (Ages 40-75)

For patients with diabetes and LDL-C ≥70 mg/dL 1:

• Start moderate-intensity statin as baseline therapy (no risk calculation required)
• Escalate to high-intensity statin if:
  • Age 50-75 years, OR
  • Multiple ASCVD risk factors present
  • Target: ≥50% LDL-C reduction

Primary Prevention (No Diabetes, LDL-C <190 mg/dL)

Calculate 10-year ASCVD risk using PCE, then apply these thresholds 3, 1:

High Risk (≥20% 10-year risk):

• Initiate moderate-to-high-intensity statin
• Target: ≥50% LDL-C reduction

Intermediate Risk (7.5% to <20% 10-year risk):

• Moderate-intensity statin recommended after risk discussion
• Target: ≥30% LDL-C reduction
• Consider risk-enhancing factors that favor statin initiation:
  • Family history of premature ASCVD
  • Persistently elevated LDL-C ≥160 mg/dL
  • Metabolic syndrome
  • Chronic kidney disease
  • History of preeclampsia or premature menopause
  • Chronic inflammatory disorders (RA, psoriasis, HIV)
  • South Asian ethnicity
  • Triglycerides ≥175 mg/dL
  • If measured: ApoB ≥130 mg/dL, hs-CRP ≥2.0 mg/L, ABI <0.9, Lp(a) ≥50 mg/dL

Borderline Risk (5% to <7.5% 10-year risk):

• Risk-enhancing factors may favor statin therapy
• Consider coronary artery calcium (CAC) scoring if uncertain

Low Risk (<5% 10-year risk):

• Emphasize lifestyle modification
• Generally no statin indicated

Using Coronary Artery Calcium for Uncertain Cases

For intermediate-risk or selected borderline-risk patients where treatment decision is uncertain 3:

• CAC = 0: Withhold statin, reassess in 5-10 years (unless diabetes, family history of premature CHD, or smoking present)
• CAC 1-99: Initiate statin if age ≥55 years
• CAC ≥100 or ≥75th percentile: Initiate statin therapy

Statin Intensity Definitions

High-intensity statins (reduce LDL-C by ≥50%):

• Atorvastatin 40-80 mg
• Rosuvastatin 20-40 mg

Moderate-intensity statins (reduce LDL-C by 30-49%):

• Atorvastatin 10-20 mg
• Rosuvastatin 5-10 mg
• Simvastatin 20-40 mg
• Pravastatin 40-80 mg
• Lovastatin 40 mg
• Fluvastatin 80 mg
• Pitavastatin 1-4 mg

Critical Pitfalls to Avoid

Do not use PREVENT equations for initial treatment decisions in statin-naive patients—they systematically underestimate risk by incorporating statin treatment effects into the baseline risk estimate 2. This would result in approximately 17 million fewer Americans receiving appropriate statin therapy 4.

Always conduct a clinician-patient risk discussion before initiating therapy in primary prevention, covering major risk factors, risk-enhancing factors, lifestyle benefits, statin benefits, potential adverse effects, drug interactions, costs, and patient preferences 1.

Do not skip risk calculation for diabetes patients aged 40-75—while they automatically qualify for at least moderate-intensity statins, calculating their risk helps determine if high-intensity therapy is warranted 1.